<DOC>
	<DOCNO>NCT00116792</DOCNO>
	<brief_summary>We hypothesize combination thin-strut MULTI-LINK ( i.e . VISION ( tm ) and/or MINI-VISION ( tm ) ) stent pharmacologic therapy oral PPAR-gamma agonist rosiglitazone significantly reduce restenosis intracoronary stenting type 2 diabetic patient . This approach would present effective economical alternative use drug-eluting stent reduce stent restenosis .</brief_summary>
	<brief_title>PROVIDENCE : Prevention Restenosis With Oral Rosiglitazone Vision Stent Diabetics With Coronary Lesions</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>The patient must &gt; 18 year age ; Patients must previously diagnose type 2 diabetes document treatment insulin , oral hypoglycemics , diet control medical history . ( Undocumented newly diagnose diabetic must fulfill American Diabetes Association CriteriaReport Expert Committee Diagnosis Classification Diabetes Mellitus ( Diabetes Care 2003 ; 26 : S520 ) ) . Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , IIIIII ) OR patient document silent ischemia ; Treatment lesion native coronary artery require stenting . A total two separate lesion stented , locate either vessel ( least 10 mm 1 cm apart ) two separate vessel . Additional stent may use procedural complication dissection . Patient willing comply specify followup evaluation ; Patient must provide write informed consent prior procedure use form approve local Institutional Review Board . Target lesion ≥2.0 mm ≤3.5mm diameter ( visual estimate ) ; Individual lesion ≤25 mm length locate native coronary artery ; Target lesion de novo lesion native coronary vessel ; Target lesion stenosis ≥50 % &lt; 100 % ( visual estimate ) ; Patient experience STsegment elevation myocardial infarction within precede 24 hour . Ejection fraction ≤40 % ; class IIIIV CHF Active liver disease ( ALT &gt; 2.5 time upper limit normal ) Woman childbearing potential unless demonstrated 1 ) negative pregnancy test 2 ) clear intention accept method contraception eight month enrollment Totally occluded vessel ( TIMI 0 grade flow ) ; Impaired renal function ( creatinine ≥2.5 mg/dL ) ; Target lesion involve bifurcation include side branch ≥2.5 mm diameter ( either stenosis main vessel major branch stenosis major branch ) would require side branch stenting likely occur side branch diseased intend stented ; Previous brachytherapy target vessel ; Recipient heart transplant ; Patient life expectancy le 12 month ; Known allergy cobalt , chromium , nickel , aspirin , clopidogrel bisulfate ( Plavix® ) and/or ticlopidine ( Ticlid® ) , heparin , and/or rosiglitazone ( Avandia® ) , medically manage ; Any significant medical condition investigator ’ opinion may interfere patient ’ optimal participation study ; Currently participate investigational drug another device study ; Any contraindication glycoprotein IIb/IIIa inhibitor therapy ; Current use TZD , i.e . rosiglitazone ( Avandia® ) pioglitazone ( Actos® ) Chronic relapse/remitting hemolytic condition Unprotected leave main coronary disease &gt; 50 % stenosis ; Patients admit treatment diabetic ketoacidosis &gt; 2 time past six month ( brittle diabetic ) and/or suspicion type I diabetes ; Target lesion saphenous venous graft internal mammary graft ; Target lesion due restenosis 3 vessel coronary artery disease define ≥70 % ischemia produce lesion 3 different epicardial coronary artery require revascularization ( i.e . main leave main equivalent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>CAD</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Restenosis</keyword>
	<keyword>ppar gamma</keyword>
	<keyword>glitazone</keyword>
</DOC>